NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (INKT), Inc. cell therapies to treat cancer and other immune-mediated diseases, today announced data from two poster presentations at the ...

MiNK Therapeutics (INKT) announced data from two poster presentations at the Society for Immunotherapy of Cancer’s 39th Annual Meeting in Houston, Texas. The presentations showcased new data from MiNK ...

Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPF Findings extend MiNK’s iNKT platform into chronic fibrotic lung disease and support immune restoration ...

(RTTNews) - MiNK Therapeutics (INKT), a clinical-stage company, said new translational data supporting the role of invariant natural killer T or iNKT cells in idiopathic pulmonary fibrosis or IPF were ...

This past Friday, July 12th, 2025, MiNK Therapeutics (INKT) closed the day higher by 730% to $64.17 per share. The reason for this massive surge in stock price was because of the release of data from ...

MiNK Therapeutics, Inc. (NASDAQ:INKT) stock is trading higher on Friday, with a session volume of 20.2 million compared to the average volume of 7.5 million as per data from Benzinga Pro. The clinical ...

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) ...

Operating Cash Burn-- Reduced Q2 operating cash burn by over 30% year-over-year, reflecting operational efficiencies. Cash Balance-- $1.7 million cash balance at Q2 2025 quarter end, plus an ...

AgenT-797 Combination with Checkpoint Inhibitors and Bispecific Engagers Expands Anti-Cancer Benefit PRAME-TCR iNKT Overcomes Challenges from Conventional TCR-T Cells in Solid Cancers NEW YORK, Nov.

“Our partnership with MiNK unites their cutting-edge iNKT manufacturing with our deep expertise in transplant immunology at the University of Wisconsin-Madison,” said Jenny E. Gumperz, PhD, Professor ...